FLAGYL ER Rx
Generic Name and Formulations:
Metronidazole 750mg; ext rel tabs.
Indications for FLAGYL ER:
Bacterial vaginosis in non-pregnant women.
Swallow whole. Take 1hr before or 2hrs after meals. 750mg once daily for 7 days. Severe hepatic impairment: not recommended. Hemodialysis: consider dose supplementation after session.
Premenarche: not established.
Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol during or at least 3 days after treatment.
Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. IV: risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after starting, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy (Cat.B). Nursing mothers: not recommended.
See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.
Nausea, headache, anorexia, vomiting, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.
Tabs—50, 100; ER—30; Caps 375mg—50
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities